about
Vaccines: from empirical development to rational designCD4(+) T Cell Priming as Biomarker to Study Immune Response to Preventive VaccinesTLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN RoutesEvaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1)Inactivated influenza vaccines: recent progress and implications for the elderly.Innate immunity against HIV: a priority target for HIV prevention researchPriorities for tuberculosis research: a systematic review.The immune space: a concept and template for rationalizing vaccine development.Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.Evaluation of Alum-Naltrexone Adjuvant Activity, on Efficacy of Anti-Leishmania Immunization with Autoclaved Leishmania major (MRHO/IR/75/ER) Antigens in BALB/C Mice.Immunological adjuvant effect of the peptide fraction from the larvae of Musca domestica.Modulation of influenza vaccine immune responses using an epidermal growth factor receptor kinase inhibitor.Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.Vaccine delivery using nanoparticles.Modulation of Primary Immune Response by Different Vaccine Adjuvants.Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform.TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine.Role of adjuvants in modeling the immune response.Adjuvants for human vaccines.Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.Combination of adjuvants: the future of vaccine design.Human immunodeficiency virus antibodies and the vaccine problem.A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine.A novel adjuvant, the mixture of alum and naltrexone, augments vaccine-induced immunity against Plasmodium berghei.Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.Particulate transepithelial drug carriers: barriers and functional polymers
P2860
Q21089599-6A865FE4-07ED-4023-8692-BD4623CC663DQ27014949-1D68D2DA-EADB-4E0D-886E-A3B2907C422DQ27322386-0E7DE3FE-8ECF-4119-B800-FFD0DD3AAD65Q30392892-C7C5174C-D385-49CD-8CAB-35FCA0BCE071Q30399057-8A6D6B80-F6CE-432E-A5CE-6EDE33C2D403Q34243462-2E01009F-81DE-4855-A5E4-99B9E92A6309Q34351616-131BA96D-9FDB-4429-9C14-FC0F6B79754CQ34399762-E2AE4030-4E83-424A-B61D-8B6D963C14ACQ34993838-1254ACCE-1312-4EFB-B031-0CB14581E3F4Q35047309-F65A2B6B-526B-493C-A08E-D07D7C3F2A2BQ35859313-F5DD8C10-8F3D-4F80-982D-374C481D23DBQ35905805-CE144AD4-1C9D-48AB-B708-695457034DECQ36517179-8C7196DB-D163-4B96-A1F3-93A84DF63179Q36712817-200F3A87-FF0E-4577-A4B3-4239A2C5E36FQ37342800-E423F9EE-2AB3-43BA-9D17-B73A132E6557Q37353525-50D27B05-9ED3-4AED-B343-BF114B8A1F93Q37771945-54223089-6C8C-4252-AACD-858496ABF37DQ37803320-D42327D1-FCB0-47E3-9B90-4BA40677BDFBQ38004229-E103F4DF-00BF-45C5-8C52-0F52A3D394C3Q38032881-81D672D0-4F97-4EF8-9852-1FD93D1BDA51Q38124060-E81C5593-5D0E-4511-AAE8-CDBB64836D12Q38192126-4E217114-F1AA-4239-9E2D-0587B2683DABQ44348323-80688FF6-B60B-413F-AC1A-F6F3E2F7B80BQ47875209-6407BEA5-0D53-4787-A232-CB095D7FB672Q53119249-746FAA75-CBE5-4611-A4DF-0ABF7B3A86C9Q58385253-7CAF9374-827B-46C5-96B6-E72F6858B1D9
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Vaccine adjuvants: a priority for vaccine research.
@en
Vaccine adjuvants: a priority for vaccine research.
@nl
type
label
Vaccine adjuvants: a priority for vaccine research.
@en
Vaccine adjuvants: a priority for vaccine research.
@nl
prefLabel
Vaccine adjuvants: a priority for vaccine research.
@en
Vaccine adjuvants: a priority for vaccine research.
@nl
P1433
P1476
Vaccine adjuvants: a priority for vaccine research.
@en
P2093
Ali M Harandi
Working Group convened by EUROPRISE
P304
P356
10.1016/J.VACCINE.2009.12.084
P407
P577
2010-01-09T00:00:00Z